menu
    • menu
    [{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"Solasia Pharma KK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Mangafodipir Trisodium","moa":"Free radical","graph1":"Oncology","graph2":"Phase III","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Egetis Therapeutics \/ Solasia Pharma KK","highestDevelopmentStatusID":"10","companyTruncated":"Egetis Therapeutics \/ Solasia Pharma KK"},{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"Solasia Pharma KK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mangafodipir Trisodium","moa":"Free radical","graph1":"Oncology","graph2":"Phase III","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Egetis Therapeutics \/ Solasia Pharma KK","highestDevelopmentStatusID":"10","companyTruncated":"Egetis Therapeutics \/ Solasia Pharma KK"},{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"Pharma Consulting Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Mangafodipir Trisodium","moa":"Free radical","graph1":"Oncology","graph2":"Phase III","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egetis Therapeutics \/ Pharma Consulting Group","highestDevelopmentStatusID":"10","companyTruncated":"Egetis Therapeutics \/ Pharma Consulting Group"},{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"University of Edinburgh | NHS Lothian","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Mangafodipir Trisodium","moa":"Free radical","graph1":"Undisclosed","graph2":"Phase I","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egetis Therapeutics \/ University of Edinburgh | NHS Lothian","highestDevelopmentStatusID":"6","companyTruncated":"Egetis Therapeutics \/ University of Edinburgh | NHS Lothian"},{"orgOrder":0,"company":"Egetis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mangafodipir Trisodium","moa":"Free radical","graph1":"Neurology","graph2":"Phase I","graph3":"Egetis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egetis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Egetis Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Mangafodipir Trisodium

    Menu

    Mangafodipir Trisodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Solasia Pharma KK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer

                            Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 26, 2019

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Solasia Pharma KK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Solasia Pharma KK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

                            Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 31, 2018

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Solasia Pharma KK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects

                            Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chemotherapy-induced Peripheral Nervous System Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 13, 2018

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : University of Edinburgh | NHS Lothian

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PP100-01 (Calmangafodipir) for Overdose of Paracetamol

                            Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 06, 2017

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : University of Edinburgh | NHS Lothian

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed

                            Egetis Therapeutics

                            Sweden arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Pharma Consulting Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer

                            Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 14, 2012

                            Lead Product(s) : Mangafodipir Trisodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Pharma Consulting Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth